Stathmin 1 expression in neuroendocrine and proliferating prostate cancer
Open Access
- 8 January 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-13
Abstract
Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. While PCa initially responds to androgen deprivation therapy, a significant portion progresses to castration-resistant PCa. Approximately 20–25% of these cases acquire aggressive neuroendocrine (NE) features, ultimately leading to neuroendocrine prostate cancer (NEPC). In this study, we investigated the expression of stathmin 1 (STMN1) across PCa subtypes using bioinformatics, western blotting, and immunohistochemical staining analyses in human and murine models. We found that elevated STMN1 expression correlated with high Gleason Scores, increased cell proliferation, and poor clinical outcomes in PCa patients. Notably, STMN1 expression was significantly higher in NEPC compared to prostate adenocarcinoma, suggesting its role in NEPC progression. Findings from TRAMP tumors, a murine NEPC model, further supported these results. In conclusion, STMN1 expression is elevated in advanced PCa, particularly in NEPC, suggesting its involvement in the progression of aggressive forms of PCa. While STMN1 shows potential as a diagnostic and prognostic marker for aggressive PCa, further studies are necessary to establish its clinical utility.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R01 CA226285)
This publication has 39 references indexed in Scilit:
- Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine CarcinomaClinical Cancer Research, 2014
- The E2F Transcription Factor 1 Transactives Stathmin 1 in Hepatocellular CarcinomaAnnals of Surgical Oncology, 2012
- RB1, Development, and Cancer2011
- Stathmin 1: a novel therapeutic target for anticancer activityExpert Review of Anticancer Therapy, 2008
- Inhibiting Proliferation and Enhancing Chemosensitivity to Taxanes in Osteosarcoma Cells by RNA Interference-Mediated Downregulation of Stathmin ExpressionMolecular Medicine, 2007
- Origin of Androgen-Insensitive Poorly Differentiated Tumors in the Transgenic Adenocarcinoma of Mouse Prostate ModelNeoplasia, 2007
- Increased expression and differential phosphorylation of stathmin may promote prostate cancer progressionThe Prostate, 2007
- Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancerMolecular Cancer Therapeutics, 2006
- Docetaxel induces cell death through mitotic catastrophe in human breast cancer cellsMolecular Cancer Therapeutics, 2005
- Distribution of phosphoprotein p19 in rat brain during ontogeny: stage-specific expression in neurons and gliaDevelopmental Brain Research, 1991